Evidence for the involvement of infl ammatory processes in the pathogenesis of Alzheimer's disease (AD) has been documented for a long time. However, the infl ammation hypothesis in relation to AD pathology has emerged relatively recently. Even in this hypothesis, the infl ammatory reaction is still considered to be a downstream eff ect of the accumulated proteins (amyloid beta (Aβ) and tau). This review aims to highlight the importance of the immune processes involved in AD pathogenesis based on the outcomes of the two major infl ammation-relevant treatment strategies against AD developed and tested to date in animal studies and human clinical trials -the use of anti-infl ammatory drugs and immunisation against Aβ.
In addition to amyloid beta (Aβ) and tau protein aggregates, the presence of immune-related antigens and cells around amyloid plaques in the brains of patients with Alzheimer's disease (AD) has been reported since the 1980s [1] [2] [3] . Th ese initial observations brought about changes to the previously assumed view of the brain as an immunologically isolated organ. In the 1990s, additional fi ndings of activated complement factors, cytokines and a wide range of related receptors in the brain of AD patients led to the concept of neuro infl ammation (infl ammation within the central nervous system (CNS)), which suggests that immunological processes in the brain are likely to be involved in the pathology of degenerative diseases of the CNS. Table 1 lists signs of an altered immune response reported in AD patients.
Th e role of aggregated proteins in the pathology of AD had to be re-considered to account for these observations. Th e infl ammation hypothesis emerged relatively recently, when it became clear that the observations of altered immune processes in AD could not be ignored. Neuroinfl ammation is still considered to be a downstream consequence in the amyloid hypothesis, with Aβ amyloid within the CNS bringing about activation of microglia, initiating a pro-infl ammatory cascade that results in the release of potentially neurotoxic substances, including cytokines, chemokines, reactive oxygen and nitrogen species, and various proteolytic enzymes, leading to degenera tive changes in neurons [4] [5] [6] [7] . It has also been suggested that activation of microglia may lead to phosphorylation of tau and formation of neurofi brillary tangles (NFTs) [8] [9] [10] . However, the exact role of infl ammation in the pathology of AD and its mechanisms in terms of the cells involved -microglia, astrocytes and T lymphocytes -are still debated.
Th e infl ammation hypothesis is also supported by epidemiological retrospective observations that patients with rheumatoid disease who are on long-term antiinfl ammatory therapy have a lower prevalence of AD [11] [12] [13] [14] [15] . Other largely observational studies have also supported the concept that anti-infl ammatory approaches may be protective against the development of AD [16, 17] . Furthermore, transgenic animal studies and human trials have demonstrated that treatment with nitric oxidereleasing non-steroidal anti-infl ammatory drugs (NSAIDs) can reduce and/or prevent the AD pathology (reviewed by McGeer and McGeer [18] ). It has also been shown that a certain drug with anti-infl ammatory properties (CNI-1493) suppresses amyloid pathology and improves memory performance in transgenic mice [19] . Despite these fi ndings, however, several prospective anti-infl ammatory strategies against disease progression in subjects with established AD have failed to show convincingly positive results (see the 'Current treatment strategies based on the infl ammation hypothesis' section below). Although these eff ects did not reach signifi cant levels in large human cohorts [20] , interest in the infl ammatory processes of AD pathology has persisted [21, 22] . One particularly interesting aspect of these studies was that (at least in animal models) the observed benefi cial action of anti-infl ammatory drugs was not necessarily attributed to down-regulation of infl ammatory processes. Instead, activation of microglia via a route that enhances its phago cytic activity against Aβ was suggested [23] .
Th e infl ammation hypothesis also suggests another approach to sporadic AD and associated risk factors for investigation -polymorphism of genes related to induc tion and regulation of infl ammatory processes. Initial studies suggested a role for specifi c cytokine polymorphismsfor example, in the genes encoding IL-1 and TNFα [24, 25] -with evidence that IL-1 polymorphism may be associated with diff ering degrees of microglial activation in AD [26] . However, a meta-analysis of genetic infl uences in AD has not supported the initial fi ndings of cytokine gene variation as a risk factor for AD, but has instead emphasised the over-riding importance of the APOE gene polymorphism as the major genetic risk factor [27] . Although many mechanisms for the role of apolipoprotein E (APOE) in AD pathogenesis have been suggested [28] , the key mechanism remains unclear. Of particular interest to the infl ammation hypothesis is the fi nding that APOE ε4 carriers with AD have more marked microglial activation [29] .
Research into the role of infl ammation in AD is driven by questions similar to those posed for Aβ and abnormal tau accumulation. Can neuroinfl ammation be the cause of AD? Are the infl ammatory processes in AD contributing to the disease pathology? Alternatively, are they merely the consequence of the disease, initiated and driven by the neurodegeneration? Does infl ammation act as a harmless bystander in the disease course? Can the immune processes of the brain be harnessed to fi ght against the disease pathology?
Infl ammation as the sole cause of AD is usually considered as unlikely on the basis that peripheral systemic disorders rarely start with infl ammation -there is an initial challenge that is required to stimulate an immune (or infl ammatory) response [30] . However, it should be noted that being a response to an insult rather than an insult itself, infl ammation plays an important role in the reaction of an organism to this insult, with potentially damaging and sometimes fatal consequences (for example, in allergy). Autoimmune diseases can aff ect the CNS (for example, paraneoplastic syndromes, multiple sclerosis) but there is little evidence to suggest that AD falls into this category.
With respect to whether infl ammatory processes in AD contribute to the disease pathology, a lot of evidence has accumulated suggesting that infl ammation can contribute to the AD process and exacerbate the course of the disease. It is still unclear exactly how infl ammation acts on the diseased brain, as most of the observations about the mechanisms of its action are based on animal models. However, the supportive evidence for infl ammation being a contributor to the disease process is as follows. First, the cognitive state of AD patients who also have shortterm peripheral infection show signs of sudden decline in cognitive state, and rarely return to the previous level even after recovery from the infection [31] . Second, community-based studies suggest that plasma levels of infl ammatory proteins, including cytokines, are increased before clinical onset of dementia, including AD [32] , which may be exacerbated by the presence of atherosclerosis [33] . Th ird, observed signs of infl ammation in the brain of AD patients are comparable to those seen in peripheral infl ammatory reactions and are likely to have a strong cytotoxic eff ect on neurons [5, 30] . Fourth, signs of infl ammation are particularly localised in the brain areas aff ected by AD pathology and co-localise with plaques and tau deposits [1, 2, [34] [35] [36] [37] [38] [39] [40] . Fifth, high pathology controls (individuals who have Aβ and tau aggregates at levels similar to AD patients, but do not develop dementia) show lower signs of infl ammation [41] . Sixth, Mini Increased hippocampal gene expression of MHC II in AD compared to high-pathology controls [95] Elevated brain levels of IL-1β and S-100 [3] Presence of activated elements of classical complement pathway (C1q, C3d, C4d) within dystrophic neurites, NFTs and/or Aβ plaques [34, 36, 96] Up-regulated mRNA levels of complement elements C1q and C9 in AD brain [97] Strong IL-6 immunoreactivity around plaques and large cortical neurons [38] Low levels of TNFα in brain areas with AD pathology [39] Increased levels of TNFα in sera of severe stage AD patients [98] Increased levels of intracellular neuronal IL10, IFNγ and IL12 in AD patients compared to age-matched controls [99] Correlations between Mini Mental State Examination scores and in vivo imaging marker [11C](R)PK11195-PET of activated microglia in AD patients [42] Mental State Examination scores of AD patients correlate with the level of cortical microglial activation as observed from in vivo imaging studies [42] . From these observations, infl ammation could contribute to the course of AD in two ways. Firstly, as an initial innate immune response to the changes in the AD brain. In the periphery, the innate immune system generates a non-specifi c response to an invading pathogen or a cell stress stimulus as a general fi rst-line defence mechanism. Infl ammation is part of this response, involving signalling via cytokines and via activation of the complement system to recruit the immune cells to the site of stress. In the periphery, this response is also often referred to as an acute, strong, but short-lived immune reaction. In the context of AD, association of microglia -the immune system cells of the CNS -with plaques and NFTs has been observed, suggesting involvement of innate immunity in the reaction to the AD-related stimuli. Observations of acute-phase infl ammatory proteins alongside cytokines and chemokines associated with plaques and tangles in AD have been reported, suggestive of multiple ways of interaction between these infl ammatory mediators [5] . Th e presence of elements of the complement system and membrane attack complex C5b-9, in particular, has been reported to correlate highly with the level of synaptic loss [41] . Th is engagement of the complement system has not been observed in the brains of high pathology controls, contributing to evidence of the involvement of acute mediators in AD. Th e C5b-9 complex is known to be very potent at killing or damaging neurons through signalling for production of various cytokines and other complement elements [30] . However, most studies refer to infl ammation in AD as weak and non-specifi c. Th is is explained on the basis of the presence of multiple mechanisms that regulate infl am matory reactions within the brain and minimise them [43] . Nevertheless, long exposure to ongoing infl am mation signalling, even at low levels, can bring about gradual neurodegeneration that might be more diffi cult to stop or reverse than acute infl ammatory episodes observed in peripheral disorders [30] . Secondly, the low-level ongoing infl ammation in AD contributing to the course of the disease can be a sign of impaired adaptive immune responses leading to chronic infl ammation. In the periphery, an innate immune response is followed by a switch to an adaptive response with generation of antibodies and overall down-regu lation of acute pro-infl ammatory signalling. Th e func tions of the adaptive immune response include induction of more specifi c and stronger defence mechanisms against abnormal stimuli, and engagement of memory T cells that can recognise and eliminate the same stimulus more quickly and effi ciently if it is encountered again in the future. Th e important feature of this type of response is to be able to recognise 'non-self' antigens and distinguish them from 'self' . In the context of AD pathology, Aβ plaques and NFTs persist, accompanied by ongoing infl ammation over a long period of time, during which the disease progresses. It is suggested, therefore, that after induction of the initial immune response, when plaques and tangles are recognised as invading stimuli, transition to the adaptive immune response and the mechanism of recognition of plaques and tangles as persisting stress stimuli is impaired. With respect to microglia in AD, this eff ect is refl ected by their inability to transit from an initial classic state (also referred to as pro-infl ammatory or Th 1-induced) to an alternative (anti-infl ammatory or Th 2-induced) immune response. Impaired activation of microglial Toll-like receptors in AD brain has also been suggested [44] [45] [46] . Th e result is that phagocytic activity as well as the neuroprotective function of microglia are impaired [47] .
Th e type of infl ammation in the AD brain is not well defi ned and is often blamed on 'dysfunctional' or 'malactivated' microglia [48] . Th e exact profi le of these microglia has not yet been well characterised [4] , but the description is often based on observation of a single marker or a dystrophic and apoptotic appearance of the cells [48] [49] [50] .
Some studies report the presence of auto-antibodies against Aβ in older people [51] , and possible involvement of T and B cells in the AD process [52, 53] . However, conclusive positive evidence for direct involvement of antibody-mediated response in AD has not yet been presented [30] .
One could also suggest that infl ammation observed in the brains of AD patients is merely a consequence of the disease, pointing to an inability of microglia to clear evergrowing neuronal debris due to extensive neuro degeneration and synaptic loss. Impaired recruitment of mono cytes from the periphery to the site of the disease in AD brain has been suggested in this respect and demon strated using animal models [54] [55] [56] .
Th e phagocytic profi le of microglia that is often referred to in AD brain is generally non-aggressive, aiming at clearing the damage/debris with minimal further damage to the surrounding tissue, leading to the question: can infl ammatory activity in AD brain have a neutral or even benefi cial role? However, another per spective comes from studies using a model of neuro degeneration -the ME7 mouse model of prion disease [57] . Th ese studies suggest that microglia in the context of a neurodegenerative disease, although generally in an anti-infl ammatory state, are 'primed' to switch quickly into an aggressive profi le should the opportunity arise. Such an opportunity may be a peripheral infection, as demonstrated in this model [58] .
Mixed and often contradictory fi ndings with respect to infl ammation in AD indicate the complexity and multi-functional role of the immune system. It became apparent that infl ammation in the CNS, as in the periphery, is a mixture of both destructive and rebuilding processes. Th e balance between these processes determines the overall integrity of the tissue or the whole organism [59] . Th erefore, infl ammation should not be viewed as wholly detrimental or benefi cial in AD. Understanding of the whole spectrum of the immune processes involved is necessary to fi nd an optimal solution for the prevention or treatment of the disease.
Th e possibility of harnessing immune processes to direct the system towards clearance of the disease features has become an actively researched topic of AD. Much AD research is now aimed at modulation of the immune system to direct it away from microglial activation that is pro-infl ammatory (or malactivated) towards a more controlled productive and phagocytic antibodymediated immune response [60] .
In summary, the pathological changes associated with AD as described above should not be considered in isolation. It is more likely that their cumulative action results in disruption of the normal work of the CNS through damage to neurotransmitter systems, neuronal dysfunction and death.
Current treatment strategies based on the infl ammation hypothesis
Two main treatment approaches addressing infl amma tory processes in AD, but from diff erent perspectives, have been investigated so far. Th e use of anti-infl ammatory drugs aims to down-regulate the infl am ma tion in AD brain for a potential benefi cial eff ect, whereas the immunotherapy approach aims to harness the immune system and direct it against the pathological features of the disease, mainly Aβ deposition. Th e advances in, and limitations of, both approaches are discussed below.
Anti-infl ammatory drugs
As mentioned above, retrospective studies of patients who were on NSAIDs long-term showed that these patients had a lower prevalence of AD. Th ese obser vations have generated interest in anti-infl ammatory strategies for AD. Th e approach was tried in APPSW and APP-PS1 transgenic mouse models of AD using nitric oxide-releasing NSAIDs [23, 61] . Both studies showed that treatment with these drugs reduces and/or prevents AD pathology in the animals. Th e involvement of microglia was suggested, but the results were contradictory, reporting decreased microglial activation in the APPSW model [61] but surprisingly raised levels of activated microglia in the APP-PS1 model [23] . An eff ect of NSAIDs in decreasing secretion of Aβ was observed in cultured cells [62] . However, the mechanism of action of the NSAIDs is not understood. Epidemiological studies show various degrees (up to 50%) of benefi cial eff ect from the use of NSAIDs on the onset of the disease and dementia, with increased duration of drug use having a positive eff ect by reducing the relative risk of AD [16, 17, 20] . However, the results from randomized controlled clinical trials did not show any benefi cial eff ect (reviewed by McGeer and McGeer [18] ). Conventional NSAIDs can also cause undesirable side-eff ects (for example, gastrointestinal ulceration) [20] .
Immunisation
Driven by the amyloid hypothesis and by observations of microglia surrounding plaques in AD, but being unable to clear the plaques in animal models of AD and in human post-mortem observations, the immunisation approach has emerged. Th e idea of modifying the immune system and directing it towards eff ective clearance of plaques has generated a lot of interest.
Animal studies
In animal models, immunotherapy has been reported to prevent the formation of and to clear existing Aβ deposits, and to remove dystrophic neurites [63] [64] [65] [66] [67] [68] [69] [70] [71] [72] [73] [74] [75] . Th e fi rst reported immunisation study used PDAPP transgenic mice and synthetic human Aβ42 peptide as the antigen [63] . Th e animals developed a high antibody response (titre 1:10,000). Complete prevention of amyloid and neuritic pathology was achieved in mice immunised at 6 weeks of age, and extensive plaque clearance was achieved in older mice immunised at 11 months of age. Older immunised animals also showed Aβ-containing cells with an activated microglial phenotype, suggestive of Fc receptor-mediated clearance of Aβ42. Signifi cant reduction in neuritic pathology as well as reactive astrocytosis were also observed in the older immunised group when compared to untreated controls.
Th is work was followed by similar studies using Tg2576 and TgCRND8 APP transgenic mice. Active immuni zation in these models showed various levels of plaque clearance (up to 50%), signifi cant behavioural improvements in older animals, and prevention of cognitive defi cit in a younger group [64, 66] .
Administration of antibodies against Aβ (m266, 3D6, 10D5, PabAβ1-42) directly into the brain or via the periphery (passive immunisation) in PDAPP transgenic mice also showed fi ndings similar to active immunisation with regard to reduction of AD-like pathology through clearance of Aβ plaques and improved memory and learning performance [65, 67, 69, 70] . In one study, however, memory defi cits were reversed even without alteration to Aβ burden [70] .
Th ese studies posed questions about possible mechanisms of plaque clearance. Amyloid-antibody complex interaction with microglial Fc receptors was suggested as one possible mechanism [65] . A non-Fc-mediated mecha nism of direct plaque destruction with F(ab΄)2 antibody fragments that lack the Fc component was also proposed [69] . However, the role of Fc receptor-mediated phagocytosis in plaque clearance after immunotherapy was questioned when Aβ clearance was observed in actively immunised phagocytosis-defi cient (FCR-/-) APP mice at levels similar to FcR non-defi cient APP mice [71] . Equally, the ability of F(ab΄)2 fragments to activate microglia and remove amyloid fi brils was questioned when another study showed that these fragments fail to activate microglia and are less eff ective than IgG antibodies at clearing plaques [76] . A two-step mechanism of plaque removal using anti-Aβ antibodies was proposed: an initial rapid decrease in Aβ deposition 24 hours after antibody administration, followed by microglia-dependent removal 3 days after antibody injection [72] . A 'sink' mechanism was also proposed in which monoclonal antibody to Aβ may attract Aβ across the blood-brain barrier from the brain into the periphery [67] .
Although these studies showed that immunisation with Aβ was successful in animals, the models used, however, did not refl ect the full pathology of AD (that is, they lacked NFTs or substantial neurodegeneration despite Aβ deposition). It was not clear from these studies if generation of anti-Aβ antibodies and removal of amyloid would show improvement of cognition in humans. Safety issues were also highlighted with respect to the acceptable and eff ective levels of antibodies that can be used in animals versus humans, the preference of the active over passive immunisation approach, and the exact mechanism of action of the vaccine [77] . Th e antibody levels in animals had to be quite high to reach the desired eff ect of Aβ removal. Th e concern was whether sufficiently high levels of anti-Aβ antibody can be safely produced in humans. A detailed mechanism of action initiated by the immunotherapy was also not established.
Despite these concerns and unanswered questions, the immunisation approach progressed to human clinical trials (see the 'Human clinical trials' section below). Following the halting of the active immunisation phase IIa trial (conducted by Elan Pharmaceuticals) due to an infl ammatory side-eff ect in a subset of patients, more recent animal immunisation studies have been focusing on induction of a controlled immune response to AD pathology that avoids strong pro-infl ammatory reaction. A necessity for a model that would refl ect the full pathology of the disease led to the generation of the triple transgenic mouse model (3×Tg-AD), which shows Aβ deposition as well as tangle formation, synaptic degeneration and behavioural impairments [78, 79] . Recent immunisation studies using this model showed that intrahippocampal administration of Aβ antibodies clears or prevents plaque formation as well as clears early phosphorylated tau [80] . Th e same group further investigated the eff ect of active and passive Aβ immunisation and demonstrated the importance of clearing both soluble Aβ and soluble tau for the improvement of cognitive performance [81] . Th e latest active immunisation animal study in the Tg2576 model aimed to show that using non-toxic, non-fi brillogenic forms of Aβ together with an adjuvant that promotes a humoral, rather than a cell-mediated, response is eff ective in removal of AD pathology without adverse infl ammatory eff ects and microhaemorrhages [75] . Th is study also confi rmed that immunisation is more eff ective at early stages of the disease. Th e same group tested active immunisation with diff erent Aβ species in young lemur primates in order to evaluate the antibody response and choose the most effi cient peptide and adjuvant for further studies in old lemurs [82] . Tau-specifi c immuni sation in various models of tauopathies is also underway [83] .
Human clinical trials
Clinical trials testing the active immunisation approach against Aβ42 were set up by Elan Pharmaceuticals. Th e fi rst multicentre randomised multiple-dose double-blind human trial (phase I) was designed to assess the antigenicity, safety and tolerability of the developed treatment, and was performed between April 2000 and June 2002. Eighty mild to moderate stage AD patients 85 years old or less were recruited in the south of the United Kingdom. Of the recruited patients, 64 received multiple doses of 50 or 225 μg of Aβ42 peptide in combination with the QS21 adjuvant (AN-1792), and 16 received adjuvant alone (placebo). Four injections were administered at weeks 0, 4, 12, and 24, with permission to administer additional injections at weeks 36, 48, 60 and 72. Patients were assessed every 2 to 3 weeks. At the end of the study, it was reported that the treatment was well tolerated. Approximately 25 to 50% of the patients who received the active treatment developed a positive immune response to AN-1792 [84] .
In June 2001, a further study was initiated with a larger patient sample (phase IIa); 375 patients were recruited in Europe and the USA, of which 300 were to receive multiple doses of 225 μg AN-1792. Th is trial was halted after several months as 18 patients developed aseptic meningoencephalitis [85] .
Th e clinical report from the phase IIa study showed that most of the patients who developed this infl ammatory side-eff ect were considered as antibody responders with varied levels of IgG and measurable IgM levels in serum, although these levels had no obvious correlation with the incidence or severity of meningoencephalitis [85] . Th e event was predominantly singular, but four patients had moderate or severe relapses. Most of the diagnosed cases presented with progressively increased confusion, headache, or lethargy. A high white blood cell count was detected in the cerebrospinal fl uid (15 to 130 cells per μl) with no signs of viral or bacterial infection. Twelve patients recovered to baseline status, and six patients continued to decline cognitively after the event.
Whilst a report on the 1-year clinical follow-up of a subset of 30 immunized AD patients from the phase IIa study suggested evidence of a reduced cognitive decline in patients who generated antibodies against β-amyloid [86], a 1-year follow-up of all patients showed no significant fi ndings on clinical outcomes [87] . Furthermore, long-term (5 year) clinical and neuropathological follow-up of patients from the phase I trial showed that despite an antibody response, no overall positive eff ect on cognition was observed -the decline was similar to control patients [88] . In the whole cohort, there was no evidence of improved survival or of an improvement in the time to severe dementia.
Neuropathological reports on patients from the phase I and IIa studies all reported similar fi ndings [88] [89] [90] [91] [92] [93] . A signifi cant reduction in Aβ pathology was evident, as well as resolution of some tau features (dystrophic neurites). Th e remaining Aβ plaques showed dense core morphology and patchy distribution in the aff ected brain areas. No eff ect on NFTs was found. Most cases also reported signs of Aβ particles within microglia, suggesting immunisation-induced Aβ phagocytosis.
A comparison between neuropathological and clinical data in eight of the immunised patients from the phase I study showed that the degree of plaque removal correlated with the mean antibody response attained during the treatment study period [88] . However, these patients had severe end stage dementia before death, including those with virtually complete plaque removal, with the exception of one patient, who had died very shortly after their fi rst immunisation dose (due to a cause unrelated to the immunisation treatment). Th e conclusion was that although immunisation with Aβ resulted in clearance of amyloid plaques in patients with AD, this clearance did not prevent progressive neurodegeneration.
Th e initial Aβ immunisation clinical trials therefore had mixed results and the information obtained has been infl uencing the development of subsequent trials. Several clinical trials involving active and passive immunisation in AD are currently underway [94] . Th ese include early phase active immunisation studies aimed at the carboxyl terminus of Aβ (amino acids 1 to 6; Novartis), passive immunisation using antibodies against the amino terminus (amino acids 33 to 40; Pfi zer) and the use of intravenous immunoglobulin (Baxter Bioscience). Later phase passive immunisation studies include the use of antibodies to the mid-region of Aβ (amino acids 13 to 28; Lilly) and to the amino terminus (Bapineuzumab; amino acids 1 to 5; Elan). Th e latter has now entered a large phase III clinical trial with initial fi ndings in an earlier study suggesting a benefi cial eff ect for subjects not carrying the APOE ε4 allele.
Conclusion
Research into the infl ammation in AD so far has demonstrated the complexity of the mechanisms involved, which interact with each other in multiple ways. Th is web of interactions makes it diffi cult to isolate any particular infl ammatory process, element or cell and pinpoint its individual role in the progress of the disease. Immunisation as one of the AD treatment approaches has led to an increased interest in the immune processes associated with this disease and highlighted their role in AD pathogenesis. Th e ability to modulate the immune system by active immunisation to generate anti-Aβ antibodies and stimulate clearance of amyloid plaques underlined the potentially benefi cial eff ect that the immune system can have on the pathology of the disease. Th e infl ammatory response side-eff ect developed by some immunised patients pointed to the complexity of the immune processes acting in the brain and their potential for harmful eff ects. Microglia, as the main representative of the immune system in the CNS, play an important role in both of these eff ects. Th eir mechanism of action in AD pathogenesis and in the context of Aβ immunisation is still not clear. Th is review aimed to highlight the necessity of approaching current and future research into AD from multiple directions, and the importance of addressing neuro-immune interactions involved in the whole course of the disease when devising potential treatment strategies.
Abbreviations Aβ = amyloid beta; AD = Alzheimer's disease; APOE = apolipoprotein E; CNS = central nervous system; IL = interleukin; NFT = neurofi brillary tangle; NSAID = non-steroidal anti-infl ammatory drug; TNF = tumour necrosis factor.
